Selective targeting of tumor vasculature using antibody molecules

US8491906B2 · kind B2 · utility

Assignees

• PHILOGEN S.P.A. · IT
• Bayer Schering Pharma AG · DE

Inventors

• Laura Borsi · Genova, IT
• Barbara Carnemolla · Genova, IT
• Enrica Balza · Genova, IT
• Patrizia Castellani · Genova, IT
• Luciano Zardi · Genova, IT
• Matthias Friebe · Berlin, DE
• Christoph-Stephan Hilger · Berlin, DE

Key dates

• Filing date: Mar 11, 2003
• Grant date: Jul 23, 2013
• Expiry date: Aug 26, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.